Glycosmedia Weekly Diabetes News - 09/03/2021

Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists

Despite the evidence for the cardio-renal benefits of SGLT2 inhibitors, there are barriers to GPs prescribing these agents. Case-based discussions between GPs and Endocrinologists about type 2 diabetes treatment including the role of SGLT2 inhibitors could overcome some of these barriers (Diabetes Research and Clinical Practice)

A potent weighted risk model for evaluating the occurrence and severity of diabetic foot ulcers

We have established potent weighted risk models for DFU onset and severity, based on which precise prevention strategies can be formulated. Modification of important risk factors may help reduce the incidence and progression of DFUs in diabetic patients (Diabetology & Metabolic Syndrome)

Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations

While eGFR testing rates are uniformly high among people with type 2 diabetes, testing rates for uACR are suboptimal and highly variable across and within the organizations examined. Guideline-recommended uACR testing should increase detection of CKD (Diabetes Care)

Efficacy and Safety of Liraglutide in Type 1 Diabetes by Baseline Characteristics in the ADJUNCT ONE and ADJUNCT TWO Randomized Clinical Trials

In ADJUNCT ONE and TWO, the efficacy and glycemic safety of liraglutide did not depend on subgroups, leaving residual beta-cell function the only identified parameter impacting the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in T1D (Diabetes, Obesity and Metabolism)

Effects of Empagliflozin on Insulin Initiation or Intensification in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from the EMPA-REG OUTCOME® Trial

In patients with type 2 diabetes and cardiovascular disease, empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose while facilitating sustained reductions in insulin requirements over time (Diabetes, Obesity and Metabolism)

Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes

A model is presented to help patients, health practitioners and policy makers identify barriers and facilitators and understand the complex interplay of physical, psychological and social factors involved when prescribing injectable therapies (Diabetic Medicine)

High incidence of type 2 diabetes in a population with normal range body mass index and individual prediction nomogram in Vietnam

This study highlighted an alarmingly high incidence of T2D in a middle-aged population with normal range BMI in Vietnam. The individual prediction nomogram with decision curve analysis for new-onset T2D would be valuable for early detection, intervention, and treatment of the condition (Diabetic Medicine)

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes (NEJM)